FORM 7  
  
MONTHLY PROGRESS REPORT

Name of Listed Issuer: **MEDXtractor Corp.** (the “**Issuer**”).

Trading Symbol: **MXT**

Number of Outstanding Listed Securities**: 36,921,425**

Date: **April 1, 2021**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The Issuer continued to experience sales and cash flow from extractor operations and continues to pursue potential new business relationships. The Issuer closed a $1,815,000 financing primarily related to its new SHAMAN project. The Issuer leased a shared additional space at a cost of $20,400 for one year for its SHAMAN-related data collection activities, and continues to collect data.**

1. Provide a general overview and discussion of the activities of management.

**Management will continue developing the businesses of the Issuer.**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**The Issuer has embarked on a new project, called SHAMAN, related to machine-learning and database analysis as it relates to enhanced decision making. The initial development project focuses on mental health probabilities. SHAMAN is a development project that does not generate revenue at this time. The Issuer recently closed a $1.815 million financing related primarily to its SHAMAN project.**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**No new business relationships.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**Other than sales in the normal course of business, the Issuer did not acquire or dispose of any material assets during the period.**

1. Describe the acquisition of new customers or loss of customers.

**The Issuer continued to expand its customer base for the purchase of its patented CO2 extractors and its alcohol-based extractors.**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None**

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**The Issuer has no employees - all activities are contract-based.**

1. Report on any labour disputes and resolutions of those disputes if applicable.

**No such developments have occurred during the period.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**The Issuer was not a party to any legal proceedings during the period.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**The Issuer has no debt.**

1. Provide details of any securities issued and options or warrants granted.

**The Issuer closed a financing. The Offering consisted of the issuance of an aggregate of 9,075,000 Units at a price of $0.20 per Unit. Each Unit consists of one common share in the capital of the Company and one common share purchase warrant (“Warrant”), with each full Warrant entitling the holder to acquire one Common Share at a price of $0.35 per Common Share for a period of 12 months from the closing of the Offering, subject to the accelerated expiry provision described below. If, on any 5 consecutive trading days occurring after four months and one day has elapsed following the closing date of the Offering, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the Canadian Securities Exchange (“Exchange”) is greater than CDN$0.60 per Common Share, the Company may provide notice in writing to the holders of the Warrants by issuance of a press release that the expiry date of the Warrants will be accelerated to the 30th day after the date on which the Company issues such press release. In connection with the Offering, the Company paid eligible finders aggregate cash finders fees of approximately $111,760 and issued 558,800 finders options to purchase Common Shares of the Company at an exercise price of $0.35 per Common Share, within 12 months from the closing date of the Offering. Proceeds from the Offering are expected to be primarily used to fund the advancement of the Company’s proprietary SHAMAN machine-learning, mental health project.**

1. Provide details of any loans to or by Related Persons.

**None.**

1. Provide details of any changes in directors, officers or committee members.

**None.**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**The Issuer continues to attract interest and sell its essential oil extractors. Covid-19 is affecting the sales dynamic causing sales delays and this may be the case for the foreseeable future. It is not possible to accurately predict the effect of Covid-19 going forward.**

**Certificate Of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer that has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: **April 1, 2021**

**James M. Durward**   
Name of Director or Senior Officer

***“James M. Durward”***  
Signature

**Chief Executive Officer**   
Official Capacity

|  |  |  |
| --- | --- | --- |
| ***Issuer Details*** | **For Month End** | **Date of Report - YY/MM/DD** |
| **Name of Issuer**  MEDXtractor Corp. | March 2021 | 2021/04/1 |
| **Issuer Address**  1150, 707 – 7th Avenue SW | | |
| **City/Province/Postal Code**  Calgary, Alberta T2P 3H6 | **Issuer Fax No.**  N/A | **Issuer Telephone No.**  403-689-3901 |
| **Contact Name**  James M. Durward | **Contact Position**  CEO | **Contact Telephone No.**  403-689-3901 |
| **Contact Email Address**  jimd@medxtractor.com | **Web Site Address**  [www.medxtractor.com](http://www.medxtractor.com) | |